Capricor Therapeutics has announced 12-month results from its phase 1/2 clinical trial called HOPE. Teenagers and young men with Duchenne muscular dystrophy experienced improvements in cardiac function and a reduction in cardiac scarring (fibrosis) after a single dose of Capricor’s cell-based therapy, CAP-1002. Upper limb function also improved in 89% of treated patients, compared to 0% in the control group. Capricor plan to initiate a double-blind, placebo-controlled HOPE-2 clinical trial in the first quarter of 2018. HOPE-2 will evaluate the safety and efficacy of multiple doses of CAP-1002 given intravenously, with upper limb function (PUL) as the primary outcome measure.
For more information, read Capricor’s press release